Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 NDC API, $ API Reference Price

1 NDC API
$ API Reference Price

FINISHED DOSAGE FORMULATIONS

3 FDF Dossiers, 2 FDA Orange Book, 1 Europe

3 FDF Dossiers
2 FDA Orange Book
1 Europe

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 12 SPI Pharma, 1 Pfanstiehl, 1 BASF, 2 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 2 Kerry, 2 Microlex e.U, 1 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

relatedExcipients
1 Rochem International Inc
12 SPI Pharma
1 Pfanstiehl
1 BASF
2 Gangwal Chemicals
1 Ingredion Pharma Solutions
2 Kerry
2 Microlex e.U
1 Pluviaendo
3 Roquette
1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
1 Shijiazhuang Huaxu Pharmaceutical
1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders, 10 Chewable & Orodispersible Aids, 9 Taste Masking, 9 Direct Compression, 4 Parenteral, 3 Disintegrants & Superdisintegrants, 3 Co-Processed Excipients, 3 Granulation, 1 API Stability Enhancers, 1 Thickeners and Stabilizers

excipientsByApplications
17 Fillers, Diluents & Binders
10 Chewable & Orodispersible Aids
9 Taste Masking
9 Direct Compression
4 Parenteral
3 Disintegrants & Superdisintegrants
3 Co-Processed Excipients
3 Granulation
1 API Stability Enhancers
1 Thickeners and Stabilizers

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 1 NEWS #PharmaBuzz

media
3 DATA COMPILATION #PharmaFlow
1 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

globalSalesInformation
1 US Medicaid Prescriptions

MARKET PLACE

4 APIs

marketPlace
4 APIs

PATENTS & EXCLUSIVITIES

6 US Patents, 5 US Exclusivities

patents
6 US Patents
5 US Exclusivities

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 98,243

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

642,766

Annual Reports (USD Million)

Finished Drug Prices

29 RELATED EXCIPIENT COMPANIES

60EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Orbactiv, 192564-14-0, Ly333328 diphosphate, Oritavancin phosphate, Oritavancin (diphosphate), Ly 333328 diphosphate

Molecular Formula

C₈₆H₁₀₃Cl₃N₁₀O₃₄P₂

Molecular Weight

1989.1 g/mol

InChI Key

PWTROOMOPLCZHB-BHYQHFGMSA-N

FDA UNII

VL1P93MKZN

1 2D Structure

Oritavancin Diphosphate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid;phosphoric acid

2.1.2 InChI

InChI=1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1

2.1.3 InChI Key

PWTROOMOPLCZHB-BHYQHFGMSA-N

2.1.4 Canonical SMILES

CC1C(C(CC(O1)OC2C3C(=O)NC(C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)C(C(=O)N3)NC(=O)C6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)OC9C(C(C(C(O9)CO)O)O)OC1CC(C(C(O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)C(C(C(=O)NC(C(=O)N6)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O.OP(=O)(O)O.OP(=O)(O)O

2.1.5 Isomeric SMILES

C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O.OP(=O)(O)O.OP(=O)(O)O

2.2 Other Identifiers

2.2.1 UNII

VL1P93MKZN

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabinohexopyranosyl)-n3''-(p-(p-chlorophenyl)benzyl)vancomycin

2. Ly 333328

3. Ly-333328

4. Ly333328

5. Orbactiv

6. Oritavancin

2.3.2 Depositor-Supplied Synonyms

1. Orbactiv

2. 192564-14-0

3. Ly333328 Diphosphate

4. Oritavancin Phosphate

5. Oritavancin (diphosphate)

6. Ly 333328 Diphosphate

7. Oritavancin Diphosphate [usan]

8. Vl1p93mkzn

9. Ly-333328 Diphosphate

10. Kimyrsa

11. Nuvocid

12. Oritavancin Diphosphate (usan)

13. Unii-vl1p93mkzn

14. Orbactiv (tn)

15. Oritavancin Bisphosphate

16. Chembl3989766

17. Chebi:83305

18. Hy-b1831a

19. Dtxsid901027688

20. Oritavancin Diphosphate [mi]

21. Oritavancin Phosphate [mart.]

22. Cs-5054

23. Oritavancin Diphosphate [vandf]

24. Oritavancin Diphosphate [who-dd]

25. Ac-32605

26. Oritavancin Diphosphately333328, Orbactiv

27. Ly 333328 Pound>>oritavancin (phosphate)

28. Oritavancin Diphosphate [orange Book]

29. D05271

30. Q27156742

31. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin Phosphate(1:2)

32. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin Phosphate(1:2) (salt)

33. (4'r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3)'-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin Phosphate (1:2) (salt)

34. (4'r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3)'-(p-(p-chlorophenyl)benzyl)vancomycin Phosphate (1:2) (salt)

35. (4r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabinohexopyranosyl)-n3-(p-(p-chlorophenyl)benzyl)vancomycin Diphosphate

36. Vancomycin, 22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n3''-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)-, (4''r)-, Phosphate (1:2)

37. Vancomycin, 22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n3''-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)-, (4''r)-, Phosphate (1:2) (salt)

2.4 Create Date

2011-08-02

3 Chemical and Physical Properties

Molecular Formula	C₈₆H₁₀₃Cl₃N₁₀O₃₄P₂
Molecular Weight	1989.1 g/mol
Hydrogen Bond Donor Count	26
Hydrogen Bond Acceptor Count	37
Rotatable Bond Count	19
Exact Mass	1986.517897 g/mol
Monoisotopic Mass	1986.517897 g/mol
Topological Polar Surface Area	717 Å²
Heavy Atom Count	135
Formal Charge	0
Complexity	3750
Isotope Atom Count	0
Defined Atom Stereocenter Count	22
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	3

4 Drug and Medication Information

4.1 Drug Indication

Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4. 4 and 5. 1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Treatment of acute bacterial skin and skin structure infections

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

5.2 FDA Pharmacological Classification

5.2.1 Pharmacological Classes

Cytochrome P450 2C9 Inhibitors [MoA]; Cytochrome P450 2D6 Inducers [MoA]; Cytochrome P450 3A4 Inducers [MoA]; Lipoglycopeptide Antibacterial [EPC]; Lipoglycopeptides [EXT]; Cytochrome P450 2C19 Inhibitors [MoA]

5.3 ATC Code

J01XA05

NDC API